Tivantinib in Treating Patients With Metastatic Prostate Cancer

NCT01519414 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

78

Enrollment

NIH

Sponsor class

Conditions

Hormone-Resistant Prostate Cancer
Prostate Adenocarcinoma
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Placebo
DRUG: Tivantinib

Sponsor

National Cancer Institute (NCI)